Natera (NTRA) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $753 million, up 38% year-over-year; 40% growth excluding revenue true-ups.

Tests Processed: 1.044 million tests, setting a new company record.

Oncology Growth: 283,000 clinical MRD units processed, a 56% increase year-over-year.

Gross Margin: Approximately 65%, driven by improved average selling prices (ASPs).

Operating Losses: Continued reduction in operating losses while investing in growth initiatives.

Cash Flow: Positive cash inflow reported for the quarter.

Guidance: Revenue guidance raised to $2.85 billion - $2.91 billion, implying 31% growth ex true-ups.

2Strategic Updates and Business Highlights

Oncology Milestones:

Signatera became the first MRD test to receive FDA approval as a companion diagnostic and PMDA approval in Japan.

NCCN issued a Category 1 recommendation for Signatera in bladder cancer, enhancing its market position.

Women's Health: Strong performance driven by new account wins and the launch of an enhanced Panorama test, which significantly reduces no-call rates.

Organ Health: Medicare published a final LCD for organ transplant surveillance, expanding coverage significantly, expected to drive improvements in Prospera ASP and volumes.

Product Development: Continued investment in clinical trials and new product launches, including the SIGNAL-ER101 study aimed at optimizing treatment for early-stage breast cancer.

3Forward Guidance and Outlook

Revenue Growth: Expectation of continued growth in the second half of 2026, driven by volume growth and stable ASPs.

ASP Projections: Current ASP for Signatera at $12.75, with potential upside driven by expanded coverage and guideline recommendations.

Cost Management: Plans to optimize COGS through workflow improvements as new products scale, targeting a long-term gross margin of over 70%.

4Bad News, Challenges, or Points of Concern

Weather Impact: Q1 volumes were artificially suppressed due to weather-related events, which may affect sequential growth expectations.

Competitive Landscape: While Natera is performing well, the presence of competitors in the MRD space raises concerns about market share erosion and the need for continued innovation.

Regulatory Risks: The timeline for achieving additional coverage through MolDX submissions remains uncertain, which could impact ASP growth in the near term.

5Notable Q&A Insights

Sustainability of Growth: Management highlighted the importance of a robust commercial team and strong clinical evidence as key drivers of sustainable growth.

Future Readouts: Anticipation of several prospective study readouts in the coming years, which could significantly influence guidelines and reimbursement.

Market Education: The presence of competitors is not expected to significantly impact Natera, as the market for MRD testing is still in its early stages, with plenty of room for growth.

Operational Efficiencies: Continued deployment of AI and automation across the business is expected to drive efficiencies and cost savings, contributing to long-term profitability. Overall, Natera reported a strong quarter with significant growth in revenue and test volumes, bolstered by strategic advancements in oncology and women's health. However, the company faces challenges from competition and regulatory uncertainties that could impact future performance.